Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement
Eric Van Belle, Antoine Rauch, Flavien Vincent, Emmanuel Robin, Marion Kibler, Julien Labreuche, Emmanuelle Jeanpierre, Marie Levade, Christopher Hurt, Natacha Rousse, Jean-Baptiste Dally, Nicolas Debry, Jean Dallongeville, Andre Vincentelli, Cedric Delhaye, Jean-Luc Auffray, Francis Juthier, Guillaume Schurtz, Gilles Lemesle, Thibault Caspar, Olivier Morel, Nicolas Dumonteil, Alain Duhamel, Camille Paris, Annabelle Dupont-Prado, Paulette Legendre, Frederic Mouquet, Berenice Marchant, Sylvie Hermoire, Delphine Corseaux, Karim Moussa, Aurelie Manchuelle, Jean-Jacques Bauchart, Valentin Loobuyck, Claudine Caron, Christophe Zawadzki, Fabrice Leroy, Jean-Christophe Bodart, Bart Staels, Jenny Goudemand, Peter J Lenting, Sophie Susen, Eric Van Belle, Antoine Rauch, Flavien Vincent, Emmanuel Robin, Marion Kibler, Julien Labreuche, Emmanuelle Jeanpierre, Marie Levade, Christopher Hurt, Natacha Rousse, Jean-Baptiste Dally, Nicolas Debry, Jean Dallongeville, Andre Vincentelli, Cedric Delhaye, Jean-Luc Auffray, Francis Juthier, Guillaume Schurtz, Gilles Lemesle, Thibault Caspar, Olivier Morel, Nicolas Dumonteil, Alain Duhamel, Camille Paris, Annabelle Dupont-Prado, Paulette Legendre, Frederic Mouquet, Berenice Marchant, Sylvie Hermoire, Delphine Corseaux, Karim Moussa, Aurelie Manchuelle, Jean-Jacques Bauchart, Valentin Loobuyck, Claudine Caron, Christophe Zawadzki, Fabrice Leroy, Jean-Christophe Bodart, Bart Staels, Jenny Goudemand, Peter J Lenting, Sophie Susen
Abstract
Background: Postprocedural aortic regurgitation occurs in 10 to 20% of patients undergoing transcatheter aortic-valve replacement (TAVR) for aortic stenosis. We hypothesized that assessment of defects in high-molecular-weight (HMW) multimers of von Willebrand factor or point-of-care assessment of hemostasis could be used to monitor aortic regurgitation during TAVR.
Methods: We enrolled 183 patients undergoing TAVR. Patients with aortic regurgitation after the initial implantation, as identified by means of transesophageal echocardiography, underwent additional balloon dilation to correct aortic regurgitation. HMW multimers and the closure time with adenosine diphosphate (CT-ADP), a point-of-care measure of hemostasis, were assessed at baseline and 5 minutes after each step of the procedure. Mortality was evaluated at 1 year. A second cohort (201 patients) was studied to validate the use of CT-ADP in order to identify patients with aortic regurgitation.
Results: After the initial implantation, HMW multimers normalized in patients without aortic regurgitation (137 patients). Among the 46 patients with aortic regurgitation, normalization occurred in 20 patients in whom additional balloon dilation was successful but did not occur in the 26 patients with persistent aortic regurgitation. A similar sequence of changes was observed with CT-ADP. A CT-ADP value of more than 180 seconds had sensitivity, specificity, and negative predictive value of 92.3%, 92.4%, and 98.6%, respectively, for aortic regurgitation, with similar results in the validation cohort. Multivariable analyses showed that the values for HMW multimers and CT-ADP at the end of TAVR were each associated with mortality at 1 year.
Conclusions: The presence of HMW-multimer defects and a high value for a point-of-care hemostatic test, the CT-ADP, were each predictive of the presence of aortic regurgitation after TAVR and were associated with higher mortality 1 year after the procedure. (Funded by Lille 2 University and others; ClinicalTrials.gov number, NCT02628509.).
Source: PubMed